Journal of the neurological sciences
A 12-month observational study on the safety, efficacy on migraine-associated symptoms and satisfaction of CGRP monoclonal antibodies in Japanese patients with migraine.
Shungo Imai, Keiko Ihara, Nobuyuki Takahashi, Seiya Ohtani, Narumi Watanabe, Chisato Iba, Kei Ishizuchi, Ryo Takemura, Jin Nakahara, Satoko Hori, Tsubasa Takizawa
Published: 202610.1016/j.jns.2026.125751
Abstract
INTRODUCTION: Calcitonin gene-related peptide monoclonal antibodies (CGRP mAbs) are effective in clinical trials and real-world settings. However, data other than headache frequency remains limited in East Asia. Thus, we investigated long-term effica…
Preview only. Read the full abstract at the source